Model‐Informed Dosing of Venetoclax in Healthy Subjects: An Exposure−Response Analysis

• Published in: Clinical and translational science Vol. 12; no. 6; pp. 625 - 632
• Main Authors: Dave, Nimita, Gopalakrishnan, Sathej, Mensing, Sven, Salem, Ahmed Hamed
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.11.2019; John Wiley and Sons Inc; Wiley
• Subjects: Apoptosis; Bioavailability; Clinical trials; Dosage; Drug dosages; Fasting; Food; Information sharing; Leukemia; Lymphocytes; Lymphocytes B; Lymphoma; Pharmacodynamics; Pharmacokinetics; Researchers; Rheumatoid arthritis; Studies

Venetoclax is an approved drug for the treatment of some hematological malignancies. Venetoclax can cause reduction in B‐lymphocyte counts as an on‐target effect. The purpose of this analysis is to quantify the relationship between venetoclax exposure and B‐lymphocyte levels to inform dosing of vene...